Navigation Links
Dana-Farber and sanofi-aventis establish cancer research alliance
Date:9/23/2010

BOSTONDana-Farber Cancer Institute's Belfer Institute of Applied Cancer Science (Belfer Institute) and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that they have entered into a collaboration and license option agreement to identify and validate novel oncology targets for further discovery and development by sanofi-aventis of novel therapeutics agents directed to such targets and related biomarkers.

Research at the Belfer Institute is focused on understanding the fundamental mechanisms of cancers, discovering and validating therapeutic targets and their clinical context in sophisticated model systems, enabling development of drug response biomarkers and supporting the discovery and development of innovative cancer treatments. Belfer Institute and sanofi-aventis' scientists will work jointly with the goal of discovering new anticancer drugs targeted at specific patient populations.

Under the terms of the agreement, Dana-Farber will receive $33 million in upfront and research funding for a minimum of three years. Dana-Farber will also be entitled to preclinical, clinical and commercial milestone payments and royalties on sales of commercial products. In return, sanofi-aventis obtains exclusive access to certain components of a transformative cancer target identification and validation platform originally developed in the laboratory of Lynda Chin, MD, the Belfer Institute's scientific director, and will also harness the strong translational capabilities of the Belfer team.

"At the Belfer Institute, our mission is to enable the discovery of novel more effective therapeutics for cancer patients. By combining our expertise in cancer genetics and translational medicine with sanofi-aventis' excellent drug discovery and development track record, this alliance has great potential to change the practice of cancer medicine," said Ronald DePinho, MD, director of Dana-Farber's Belfer Institute and professor of medicine and genetics at Harvard Medical School.

Giulio Draetta, MD, PhD, Dana-Farber's chief research business development officer and deputy director of the Belfer Institute, added "Our alliances with major pharmaceutical companies attest to our ability to be recognized as a partner in the translation of breakthrough discoveries into anti-cancer drugs. Our ability to integrate efforts at the Belfer Institute with those of other Dana-Farber's integrative research centers of excellence contributes to making our operations extremely efficient, providing a continuum of activities from discovery to clinical implementation."

"Translating research findings from academia to developing cancer drugs in the industry is a complex task that requires the collaboration of the best in the field," declared Debasish Roychowdhury, M.D., senior vice president, head of Global Oncology Division, sanofi-aventis. "We have an obligation to discover new medicines. This innovative collaboration structure with the Belfer Institute, an entirely novel organization, will strengthen sanofi-aventis Oncology's commitment to accomplish our goals."


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Related biology news :

1. Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test
2. McMaster, NVIDIA establish first CUDA Teaching Centre in Canada
3. Genome comparison of ants establishes new model species for molecular research
4. Stomach bacteria need vitamin to establish infection
5. New breast cancer committee to establish federal research agenda
6. 6 new research units established
7. DFG establishes 12 new research training groups
8. Covance Establishes New Discovery & Translational Services Group
9. New Tree of Life established for one of the largest groups of bacteria
10. Covance Establishes New Discovery & Translational Services Group
11. Innovalight Establishes New Record With Silicon Ink Solar Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology: